ClinicalTrials.Veeva

Menu
E

Elligo Health Research | Austin, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ranibizumab
EYE103
Aflibercept

Parent organization

This site is a part of Elligo Health Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 4 total trials

A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO (Super Tuscan)

EYE-RES-104 is a randomized, dose-masked study of intravitreal EYE103 in participants with neovascular age-related macular degeneration (NVAMD) or ma...

Enrolling
Neovascular Age-Related Macular Degeneration (NVAMD)
Branch Retinal Vein Occlusion (BRVO)
Drug: EYE103
Drug: Aflibercept 2.0 mg

EYE-RES-103 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active...

Enrolling
Diabetic Macular Edema (DME)
Drug: EYE103
Drug: Ranibizumab

EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active...

Active, not recruiting
Diabetic Macular Edema (DME)
Drug: EYE103
Drug: Ranibizumab

Trial sponsors

E

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems